GDPR Art.35 DPIA · Informed Consent Form (ICF) · Data Processing Agreement (DPA) · DPO Appointment — VS-4
Name of processing activity: Holistic Clinical Science Trail — Multi-Modal Biometric Biomarker Capture
Controller: Dr. Johannes K. (Independent Integrative Medicine Practice, USA)
Processor: Lebensfluss e.V. / OHM Institute (Austria) — GDPR Art. 28 DPA in effect
Data types processed (all Art.9 special categories):
Legal basis: GDPR Art. 9(2)(a) — Explicit consent; GDPR Art. 9(2)(j) — Scientific research with Art. 89 safeguards; Austrian DSG § 2d.
The processing is necessary for the stated scientific research purpose (longitudinal holistic biomarker correlation study). Data minimisation is applied as follows:
| Risk | Likelihood | Severity | Residual Risk | Mitigation |
|---|---|---|---|---|
| Re-identification from ZKP Merkle data | LOW | HIGH | MEDIUM | ZKP hashes are one-way; no biometric raw data stored remotely |
| Unauthorised access to local biometric files | MEDIUM | HIGH | MEDIUM | Full-disk encryption on practitioner device; HIPAA physical safeguards |
| Cross-border transfer US→EU without adequacy | LOW | HIGH | LOW | DPA with SCC (Standard Contractual Clauses) between controller (US) and processor (EU) |
| Consent withdrawal — data not deleted | LOW | MEDIUM | LOW | ZKP commitment deletion protocol: practitioner deletes Merkle leaf; token orphaned |
| Scope creep — wellness tool used diagnostically | MEDIUM | HIGH | LOW | MDR Scope Firewall in all UIs; XAI disclaimer mandatory; practitioner training |
| Data breach — ZKP Merkle Tree server | LOW | MEDIUM | LOW | ZKP hashes alone are not personal data; no raw biometrics server-side |
After applying all technical and organisational safeguards described above, the residual risks associated with this processing activity are assessed as ACCEPTABLE. The processing is necessary, proportionate, and consistent with the rights and freedoms of data subjects. DPA consultation with the supervisory authority (Österreichische Datenschutzbehörde) is not required as residual risk is low after mitigation measures.
This ICF template complies with Declaration of Helsinki (WMA 2013), GDPR Art. 9(2)(a), Austrian DSG § 2d, and Good Clinical Practice (ICH E6 R2).
This DPA governs the relationship between the US Controller and EU Processor, including SCC for cross-border transfers (EU Commission Decision 2021/914/EU — Module 1: Controller-to-Processor).
GDPR Art.37(1)(c) requires DPO appointment when processing special-category data (Art.9) on a large scale. As the Vera Clinical platform processes biometric and health data, a DPO must be appointed and registered with the Austrian Datenschutzbehörde (DSB).
| Processing Activity | Category | Legal Basis | Retention | Recipients |
|---|---|---|---|---|
| Holistic biomarker research | Health + Biometric (Art.9) | Art.9(2)(a)+(j) | Study + 5yr | PI, Ethics Committee |
| ZKP Merkle commitments | Pseudonymised hashes | Art.89 research | Indefinite (audit) | Research platform only |
| EUDI consent signatures | Digital identity assertion | Art.9(2)(a) | Study lifetime | PI, DPO |